A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe

BACKGROUND: Bone metastases (BMs) are common in patients with prostate cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, reduce the incidence of SREs a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Bone Oncol
Hlavní autoři: Body, Jean-Jacques, von Moos, Roger, Rider, Alex, Hallworth, Pamela, Bhowmik, Debajyoti, Gatta, Francesca, Hechmati, Guy, Qian, Yi
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319023/
https://ncbi.nlm.nih.gov/pubmed/30627511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2018.100212
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky